Glioma
Conditions
Brief summary
The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.
Detailed description
Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and their management complex. The molecular profiling from circulating exosomes is one of the most promising approaches to better characterize gliomas. We will demonstrate the superiority of detection by NGS of molecular abnormalities present in exosomes from glioblastomas, compared to detection by the Foundation One Liquid CDx test on ctDNA.
Interventions
GENETICBlood sampling
Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
Sponsors
University Hospital, Limoges
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject of both sexes at least 18 years of age with glioblastoma. * Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol) * Patient affiliated to French social security
Exclusion criteria
* Patient included in another research protocol using an experimental molecule. * Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol * Patient under legal protection, guardianship or curatorship * Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analyse Next-generation sequencing (NGS) | 3 months | Higher proportion of contributory samples identified by NGS analysis (via exosomes) compared to that of FMI (Foundation Medicine International) test (at inclusion) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Expression of biomarkers | 3 months | Level of expression of biomarkers, for the same patient, by molecular analysis of exosomes and blood sampling according to the FMI test protocol |
| Molecular alterations | 3 months | Modification or not modification of the profile of the molecular alterations |
| carbon footprint | 3 months | Evaluation of the carbon footprint for each of the 2 techniques (NGS via exosomes and FMI test) |
Countries
France
Outcome results
None listed